iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
September 07 2021 - 4:30PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
today announced that it will participate in the H.C. Wainwright
23rd Annual Global Investment Conference, to be held virtually
September 13-15, 2021.
iBio's pre-recorded presentation will be
available on demand during the event for all registered attendees.
Beginning on Monday, September 13, 2021, the presentation will also
be available on the Company's website at www.ibioinc.com under
"News & Events" in the Investors section.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary biopharmaceuticals for the treatment of cancers, as
well as fibrotic and infectious diseases. The Company’s subsidiary,
iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services along with
Glycaneering™ Development Services for advanced
recombinant protein design. For more information, visit
www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024